NeuroScientific Biopharmaceuticals Ltd (ASX:NSB) has made a decisive move with its proposed acquisition of StemSmart™, a patented mesenchymal stromal cell (MSC) technology. This isn’t just another biotech transaction — it signals a strategic leap into the fast-growing field of regenerative medicine, positioning NSB to capitalise on one of the most promising frontiers in modern healthcare.

Astute investors will vouch that there is no such thing as a perfect investment opportunity, and at the Samso platform, we agree and we encourage followers to instead look for the ideal Risk-Reward proposition. However. Investors continue to look for that perfect investment opportunity that is, for some reason is extremely hard to find.

When a junior gold producer strategically adds a proven asset like the Henty Gold Mine to its portfolio, it doesn’t just reshape the company—it often redefines its position in the gold space.

In a fast-evolving education sector dominated by digital disruption and shifting learner expectations, OpenLearning Limited (ASX: OLL) continues to chart a bold course through its AI-powered Learning Management System. At the heart of this story is a recent milestone: a debt-to-equity conversion with the Education Centre of Australia (ECA), the company’s largest shareholder, which underscores long-term confidence in OpenLearning’s direction.

In a bold move that underscores its commitment to unlocking value from one of Australia’s most fertile gold provinces, E79 Gold Mines Limited (ASX: E79) has identified several compelling new drill targets at its Laverton South Project. This follows a comprehensive regional review and reinterpretation of large-scale geophysical datasets, inspired partly by the recent Lighthorse discovery by neighbour KalGold (ASX: KAL).

Emyria Limited (ASX: EMD) embodies the fusion of compassionate care, groundbreaking science, and a market in dire need of change. Recently, the company has gained attention by uniquely creating a scalable, evidence-based model for psychedelic-assisted therapy within licensed medical settings in Australia.

In a world where major mineral discoveries are increasingly elusive and hidden beneath cover, Geoscience Australia has crafted a powerful lens into the Earth’s potential—mineral systems-based prospectivity mapping. This approach, backed by decades of data and a deep understanding of geology, is turning Australia into a frontier once again, particularly in the hunt for Iron Oxide Copper-Gold (IOCG) deposits.

Melbourne-based biotech innovator Algorae Pharmaceuticals (ASX: 1AI) is setting the stage for a game-changing therapeutic breakthrough with its combination drug candidate, AI-116, aimed at treating dementia and neurodegenerative disorders.

Heavy Rare Earths Limited (ASX: HRE) has released a March 2025 exploration update that signals major progress across its uranium portfolio. With projects in the uranium-rich Curnamona Province of South Australia and the Mid West region of Western Australia, the company is moving aggressively to define targets through passive seismic, airborne surveys, and historical data analysis.

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) has unveiled compelling Phase 2 clinical trial data for its lead drug candidate, ATH434—a major advancement in treating Multiple System Atrophy (MSA). The findings were presented at the prestigious European MSA Symposium in London, drawing attention from global experts in neurodegenerative research.